Arax Advisory Partners’s Maze Therapeutics MAZE Stock Holding History
Bought
Maintained
Sold
Other funds holding MAZE
Arax Advisory Partners's MAZE Position: Q3 2026 in Review
Arax Advisory Partners increased its Maze Therapeutics (MAZE) stake by 117% in Q3 2026, buying an estimated $5K and bringing the position to 334 shares worth $9.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4458.
Arax Advisory Partners first reported a position in MAZE in Q3 2025 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.
- Arax Advisory Partners held 334 shares of Maze Therapeutics worth $9.08K as of Q3 2026.
- Arax Advisory Partners bought 180 Maze Therapeutics shares in Q3 2026, an estimated $5K.
- Maze Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4458 holding.
- Arax Advisory Partners first reported a position in Maze Therapeutics in Q3 2025 and has held it in 3 quarters since.
- 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.
Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.